Clinical Trial Update: A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating patritumab deruxtecan for breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Patritumab Deruxtecan (patritumab deruxtecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Breast Neoplasms | Phase 3 | Status: RECRUITING